Please login to the form below

Not currently logged in
Email:
Password:

siltuximab

This page shows the latest siltuximab news and features for those working in and with pharma, biotech and healthcare.

EC approves Janssen rare blood disorder drug

EC approves Janssen rare blood disorder drug

Sylvant (siltuximab) offers a more promising alternative, however, and has demonstrated in clinical trials it can reduce the size of tumours and stabilise disease symptoms, such as fever. ... Not every MCD patient will be eligible for treatment with

Latest news

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castleman’s disease

    Sylvant (siltuximab), marketed by Johnson &Johnson subsidiary Janssen Biotech, is the first drug backed by the FDA to treat multicentric Castleman's disease, which the agency describes as a rare disorder

  • J&J files rare blood disorder drug siltuximab in US and EU J&J files rare blood disorder drug siltuximab in US and EU

    Johnson &Johnson (J&J) has filed for approval of its investigational drug siltuximab in both the EU and US as a treatment for a rare blood disorder. ... The submissions are based primarily on data from the randomised MCD2001 study, which compared

  • J&J positive about pipeline

    Also on the list are fulranumab for osteoarthritis pain; siltuximab for castleman's disease, a rare disorder that is similar to lymphoma; TMC-207 for MDR tuberculosis; TMC 435 for hepatitis

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics